We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer expects total revenues for 2026 to be between $59.5 billion and $62.5 billion, which represents modest growth from the revised 2025 revenue expectation of around $62 billion (previous guidance: $61-$64 billion) due to lower revenues from COVID products, Comirnaty and Paxlovid, and loss of revenues from the upcoming patent cliff. Some of Pfizer’s major products are due to lose patent protection in the next few years. Revenues from COVID products are expected to be approximately $1.5 billion lower than the expected figure for 2025. Excluding COVID-19 products and the LOE cliff, Pfizer expects operational revenue growth of about 4% in 2026.
In 2026, Pfizer expects adjusted earnings per share in the range of $2.80-$3.00, which represents a decline from the 2025 expected range of $3.00 and $3.15 due to the dilutive impact of 3SBio and Metsera deals, lower COVID revenues and higher taxes.
The guidance has raised concerns among investors, leading to the big question: Is it the right time to buy PFE shares, or should one book profits? Let’s delve deeper into the company’s fundamentals to better analyze how to play the stock.
PFE Enjoys a Strong Position in Oncology
Pfizer is one of the largest and most successful drugmakers in oncology. The addition of Seagen strengthened its position in oncology.
Oncology sales comprise around 28% of its total revenues. Its oncology revenues have risen 7% in the first nine months of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer also advanced its oncology clinical pipeline with several candidates entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its portfolio.
Pfizer is also working on expanding the labels of its approved products (oncology as well as non-oncology) like Padcev, Adcetris, Litfulo, Nurtec, Velsipity and Elrexfio, among others.
This year, it in-licensed exclusive global ex-China rights to develop, manufacture and commercialize SSGJ-707, a dual PD-1 and VEGF inhibitor, from China’s 3SBio. Dual PD-1/VEGF inhibitors have been designed to overcome the limitations of single-target cancer therapies and have the potential to become a new standard of care oncology treatment.
PFE’s New & Acquired Products Driving Top-Line Growth
Pfizer’s dependence on its COVID business has now reduced. Pfizer’s non-COVID operational revenues are improving, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen (December 2023). Pfizer's recently launched and acquired products rose approximately 9% operationally in the nine months of 2025, with the momentum expected to continue. Pfizer expects its new and acquired products to deliver double-digit growth in 2026.
Pfizer is also trying to rebuild its pipeline through acquisitions. In the first nine months of this year, Pfizer invested approximately $1.6 billion in business development transactions, primarily reflecting the 3SBio licensing deal. In addition, the recent $10 billion Metsera acquisition has brought Pfizer back into the lucrative obesity space after it scrapped the development of danuglipron, a weight-loss pill, earlier this year. The acquisition will add Metsera’s four novel clinical-stage incretin and amylin programs, which are expected to generate billions of dollars in peak sales. However, the Metsera candidates are in early- to mid-stage development and still some years away from commercialization.
Earlier this month, Pfizer in-licensed exclusive global rights to develop YP05002, an oral small molecule GLP-1 receptor agonist (GLP-1 RA) for treating obesity from Chinese biotech YaoPharma.
Lower Sales of COVID Products
Pfizer is seeing a softness in sales of its COVID products, Comirnaty and Paxlovid, due to lower vaccination rates and COVID infection rates.
Changes in recommendations for COVID vaccines may result in lower vaccination rates in certain markets. For instance, in September 2025, the ACIP voted to adopt a “shared clinical decision-making” approach for all FDA-approved COVID-19 vaccines, like Comirnaty. The decision narrowed the recommendation for Comirnaty, reducing the eligible population for the vaccine and hurting its sales in the United States in the third quarter.
In 2025, Paxlovid has seen lower demand as a result of lower infection rates. In 2026, Pfizer expects its COVID revenues to be around $5 billion, $1.5 billion less than expected sales of about $6.5 billion in 2025 as COVID infection rates are expected to continue to decline.
PFE’s Other Headwinds
Pfizer expects a significant negative impact on revenues from the loss of exclusivity (“LOE”) in the 2026-2030 period as several of its key products, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, face patent expirations. The LOE cliff is expected to hurt sales by approximately $1.5 billion in 2026.
Unfavorable impact from the Medicare Part D redesign under the Inflation Reduction Act (IRA) is hurting Pfizer’s revenues in 2025. Higher-priced drugs, including Eliquis, Vyndaqel, Ibrance, Xtandi and Xeljanz, are most affected by the IRA.
PFE Stock’s Price, Estimates & Valuation
Pfizer’sstock has lost 4.9% so far this year against an increase of 16.7% for the industry. The stock has also underperformed the sector and the S&P 500, as seen in the chart below.
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its five-year mean. Going by the price/earnings ratio, Pfizer’s shares currently trade at 8.04 forward earnings, significantly lower than 17.11 for the industry as well as the stock’s five-year mean of 10.41. The stock is also much cheaper than other large drugmakers like AbbVie (ABBV - Free Report) , Novo Nordisk, Eli Lilly (LLY - Free Report) , AstraZeneca (AZN - Free Report) , J&J and others.
PFE Stock Valuation
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for earnings has risen from $3.07 per share to $3.12 for 2025, while the same for 2026 has declined from $3.15 per share to $3.07 per share over the past 60 days.
PFE Estimate Movement
Image Source: Zacks Investment Research
Stay Invested in PFE Stock
Pfizer stock has taken a beating for the past three years as its revenues have declined substantially due to lower sales of its COVID products. In addition to COVID-19 product-related uncertainty, Pfizer faces some other challenges, like U.S. Medicare Part D headwinds and the upcoming LOE cliff in the 2026-2030 period.
However, Pfizer’s key drugs like Vyndaqel, Padcev and its recently launched and acquired products should help the company largely offset its LOEs over the next several years. Pfizer expects cost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027. Pfizer’s dividend yield stands at around 7%, which is impressive. The drug pricing agreement with the Trump administration was an important milestone for Pfizer, as it provides longer-term clarity on the company’s strategic investment in innovation and growth.
Despite the lukewarm guidance update, we believe investors should continue to retain this Zacks Rank #3 (Hold) stock in their portfolio as Pfizer rebuilds its pipeline in oncology and obesity, which it believes can drive growth from 2029 and beyond. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Pfizer Down After It Issues Muted 2026 Outlook: How to Play the Stock
Key Takeaways
Pfizer (PFE - Free Report) stock has declined around 3% this week. On Dec. 16, the company announced its financial guidance for 2026, which fell short of investor expectations.
Pfizer expects total revenues for 2026 to be between $59.5 billion and $62.5 billion, which represents modest growth from the revised 2025 revenue expectation of around $62 billion (previous guidance: $61-$64 billion) due to lower revenues from COVID products, Comirnaty and Paxlovid, and loss of revenues from the upcoming patent cliff. Some of Pfizer’s major products are due to lose patent protection in the next few years. Revenues from COVID products are expected to be approximately $1.5 billion lower than the expected figure for 2025. Excluding COVID-19 products and the LOE cliff, Pfizer expects operational revenue growth of about 4% in 2026.
In 2026, Pfizer expects adjusted earnings per share in the range of $2.80-$3.00, which represents a decline from the 2025 expected range of $3.00 and $3.15 due to the dilutive impact of 3SBio and Metsera deals, lower COVID revenues and higher taxes.
The guidance has raised concerns among investors, leading to the big question: Is it the right time to buy PFE shares, or should one book profits? Let’s delve deeper into the company’s fundamentals to better analyze how to play the stock.
PFE Enjoys a Strong Position in Oncology
Pfizer is one of the largest and most successful drugmakers in oncology. The addition of Seagen strengthened its position in oncology.
Oncology sales comprise around 28% of its total revenues. Its oncology revenues have risen 7% in the first nine months of 2025, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev. Pfizer has ventured into the oncology biosimilars space and markets six biosimilars for cancer. Pfizer also advanced its oncology clinical pipeline with several candidates entering late-stage development. By 2030, it expects to have eight or more blockbuster oncology medicines in its portfolio.
Pfizer is also working on expanding the labels of its approved products (oncology as well as non-oncology) like Padcev, Adcetris, Litfulo, Nurtec, Velsipity and Elrexfio, among others.
This year, it in-licensed exclusive global ex-China rights to develop, manufacture and commercialize SSGJ-707, a dual PD-1 and VEGF inhibitor, from China’s 3SBio. Dual PD-1/VEGF inhibitors have been designed to overcome the limitations of single-target cancer therapies and have the potential to become a new standard of care oncology treatment.
PFE’s New & Acquired Products Driving Top-Line Growth
Pfizer’s dependence on its COVID business has now reduced. Pfizer’s non-COVID operational revenues are improving, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen (December 2023). Pfizer's recently launched and acquired products rose approximately 9% operationally in the nine months of 2025, with the momentum expected to continue. Pfizer expects its new and acquired products to deliver double-digit growth in 2026.
Pfizer is also trying to rebuild its pipeline through acquisitions. In the first nine months of this year, Pfizer invested approximately $1.6 billion in business development transactions, primarily reflecting the 3SBio licensing deal. In addition, the recent $10 billion Metsera acquisition has brought Pfizer back into the lucrative obesity space after it scrapped the development of danuglipron, a weight-loss pill, earlier this year. The acquisition will add Metsera’s four novel clinical-stage incretin and amylin programs, which are expected to generate billions of dollars in peak sales. However, the Metsera candidates are in early- to mid-stage development and still some years away from commercialization.
Earlier this month, Pfizer in-licensed exclusive global rights to develop YP05002, an oral small molecule GLP-1 receptor agonist (GLP-1 RA) for treating obesity from Chinese biotech YaoPharma.
Lower Sales of COVID Products
Pfizer is seeing a softness in sales of its COVID products, Comirnaty and Paxlovid, due to lower vaccination rates and COVID infection rates.
Changes in recommendations for COVID vaccines may result in lower vaccination rates in certain markets. For instance, in September 2025, the ACIP voted to adopt a “shared clinical decision-making” approach for all FDA-approved COVID-19 vaccines, like Comirnaty. The decision narrowed the recommendation for Comirnaty, reducing the eligible population for the vaccine and hurting its sales in the United States in the third quarter.
In 2025, Paxlovid has seen lower demand as a result of lower infection rates. In 2026, Pfizer expects its COVID revenues to be around $5 billion, $1.5 billion less than expected sales of about $6.5 billion in 2025 as COVID infection rates are expected to continue to decline.
PFE’s Other Headwinds
Pfizer expects a significant negative impact on revenues from the loss of exclusivity (“LOE”) in the 2026-2030 period as several of its key products, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, face patent expirations. The LOE cliff is expected to hurt sales by approximately $1.5 billion in 2026.
Unfavorable impact from the Medicare Part D redesign under the Inflation Reduction Act (IRA) is hurting Pfizer’s revenues in 2025. Higher-priced drugs, including Eliquis, Vyndaqel, Ibrance, Xtandi and Xeljanz, are most affected by the IRA.
PFE Stock’s Price, Estimates & Valuation
Pfizer’s stock has lost 4.9% so far this year against an increase of 16.7% for the industry. The stock has also underperformed the sector and the S&P 500, as seen in the chart below.
PFE Stock Underperforms Industry, Sector & S&P 500
From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its five-year mean. Going by the price/earnings ratio, Pfizer’s shares currently trade at 8.04 forward earnings, significantly lower than 17.11 for the industry as well as the stock’s five-year mean of 10.41. The stock is also much cheaper than other large drugmakers like AbbVie (ABBV - Free Report) , Novo Nordisk, Eli Lilly (LLY - Free Report) , AstraZeneca (AZN - Free Report) , J&J and others.
PFE Stock Valuation
The Zacks Consensus Estimate for earnings has risen from $3.07 per share to $3.12 for 2025, while the same for 2026 has declined from $3.15 per share to $3.07 per share over the past 60 days.
PFE Estimate Movement
Stay Invested in PFE Stock
Pfizer stock has taken a beating for the past three years as its revenues have declined substantially due to lower sales of its COVID products. In addition to COVID-19 product-related uncertainty, Pfizer faces some other challenges, like U.S. Medicare Part D headwinds and the upcoming LOE cliff in the 2026-2030 period.
However, Pfizer’s key drugs like Vyndaqel, Padcev and its recently launched and acquired products should help the company largely offset its LOEs over the next several years. Pfizer expects cost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027. Pfizer’s dividend yield stands at around 7%, which is impressive. The drug pricing agreement with the Trump administration was an important milestone for Pfizer, as it provides longer-term clarity on the company’s strategic investment in innovation and growth.
Despite the lukewarm guidance update, we believe investors should continue to retain this Zacks Rank #3 (Hold) stock in their portfolio as Pfizer rebuilds its pipeline in oncology and obesity, which it believes can drive growth from 2029 and beyond. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.